摘要
目的探讨乳腺癌患者血清糖类抗原(carbohydrate antigen,CA)153、CA125、癌胚抗原(carcinoem-bryonic antigen,CEA)和淋巴细胞与单核细胞绝对值的比值(lymphocyte/monocyte ratio,LMR)联合检测的临床意义。方法检测80例乳腺癌患者、80例乳腺良性肿瘤患者和80名健康女性的血清CA153,CA125,CEA和LMR的含量。结果乳腺癌组CA153,CA125,CEA和LMR均高于乳腺良性肿瘤组,两者比较差异具有统计学意义(P<0.05)。乳腺癌组CA153,CA125和CEA均高于正常对照组,两者比较差异具有统计学意义(P<0.05),乳腺癌组LMR与正常对照组比较差异无统计学意义(P>0.05)。乳腺良性肿瘤组CA153,CA125,CEA和LMR与正常组比较差异均无统计学意义(P>0.05)。乳腺癌Ⅰ~Ⅱ期患者与Ⅲ期患者之间CA153,CA125,CEA和LMR差异无统计学意义(P>0.05)。CA153、CEA、CA125、LMR的受试者工作特征(receiver operating characteristic,ROC)曲线下面积分别为0.861、0.720、0.695、0.614,联合检测的ROC曲线下面积为0.904。结论CA153,CA125,CEA和LMR的联合检测可以提高乳腺癌诊断的敏感度和特异度,对乳腺癌的筛查和良恶性鉴定具有重要的参考价值。
Objective To investigate the variations and their clinical significance of serum CA153,CA125,and CEA,LMR in breast cancer patients.Methods Serum levels of CA153,CA125,CEA,LMR were detected in 80 patients with breast cancer,80 patients with benign breast diseases and 80 healthy women(as controls).Results In the breast cancer group,CA153,CA125,CEA and LMR were all higher than those in the benign breast diseases group,and the difference was statistically significant(P<0.05).The comparison of CA153,CA125 and CEA in patients with breast cancer was higher than that in healthy controls,and the difference was statistically significant(P<0.05).LMR in patients with breast cancer was not statistically significant(P>0.05).There were no statistically significant differences in CA153,CA125,CEA and LMR between the benign breast diseases group and the healthy controls(P>0.05).There were no statistically significant differences in CA153,CA125,CEA and LMR between breast cancer stageⅠ-Ⅱpatients and stageⅢpatients(P>0.05).The area under receiver operating characteristic(ROC)curves of CA153,CEA,CA125 and LMR was 0.861,0.720,0.695 and 0.614,respectively.The area under ROC curves of the combined detection was 0.904.Conclusion Combined detection of CA153,CA125,CEA and LMR can improve the sensitivity and specificity of breast cancer diagnosis,and has important reference value for screening breast cancer and diffentiating benign breast cancer from malignant ones.
作者
刘钊
侯吉学
石永奎
宋延刚
刘振楠
黄桂林
LIU Zhao;HOU Ji-xue;SHI Yong-kui(The Second Department of General Surgery,the First Affiliated Hospital of the Medical School,Shihezi University,Shihezi,Xinjiang 832000,China)
出处
《实用医药杂志》
2019年第6期490-492,496,共4页
Practical Journal of Medicine & Pharmacy